Research Article Development of Atorvastatin Calcium Biloaded Capsules for Oral Administration of Hypercholesterolemia Chitra Karthikeyini Senthilvel , 1 Kavitha Karuppaiyan, 2 Ananth Pothumani, 1 Ananthi Vedharethinam, 1 Ancy Wilfred Jose, 1 Jamal Moideen Muthu Mohamed , 3 Mohamed El Sherbiny , 4 Hasnaa Ali Ebrahim, 5 Mohamed El Shafey, 6,7 and Minilu Dejene 8 1 K. M. College of Pharmacy, Madurai 625107, Melur Road, Uthangudi, Tamil Nadu, India 2 Department of Pharmaceutical Technology, BIT Campus, Anna University, Tiruchirappalli 620024, Tamil Nadu, India 3 College of Pharmacy, Shri Indra Ganesan Institute of Medical Science, Tiruchirappalli 620012, Tamil Nadu, India 4 Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, Riyadh 11597, P.O. Box 71666, Saudi Arabia 5 Department of Basic Medical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh 11671, P.O. Box 84428, Saudi Arabia 6 Department of Anatomy and Embryology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt 7 Physiological Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia 8 Department of Biotechnology, College of Biological and Chemical Engineering, Addis Ababa Science and Technology University, Addis Ababa, Ethiopia Correspondence should be addressed to Chitra Karthikeyini Senthilvel; chithirraanbalaghan@gmail.com Received 16 February 2022; Revised 14 March 2022; Accepted 17 March 2022; Published 16 May 2022 Academic Editor: Hiwa M. Ahmed Copyright © 2022 Chitra Karthikeyini Senthilvel et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. e goal of this study was to develop atorvastatin (ATN) calcium biloaded, i.e., immediate release (IR) and sustained release (SR) capsules that would promote the quick onset of action and a better dissolution profile on both the IR and SR aspects. e IR granules were prepared by the wet granulation method, and an aqueous solubility study proved that the IR granules released the ATN within 25 min compared to the pure drug due to the addition of PEG and super disintegrants such as croscarmellose (CC) and crospovidone (CP). e sustained release nanoparticles (SR-NPs) were synthesized using a solvent evaporation technique and an optimal combination of hydrophilic and hydrophobic polymers. e addition of a hydrophobic polymer to a hydrophilic polymer delays drug release, resulting in a sustained and controlled release lasting up to 12 hours. e drug release of ATN from SR nanoparticles followed the Higuchi and Korsmeyer–Peppas models and had first-order kinetics (r2  ???). Fourier transform infrared spectrophotometry, powder X-ray diffraction, and differential scanning calorimetric analysis were used to test the prepared biloaded capsules, and the results showed that there was no significant interaction between the polymers, excipients, and drug. e SEM and DLS analysis clearly demonstrated that drug particles in a continuous layer were enclosed by polymers at the nanoscale. To summarise, integrating both layers into a single capsule resulted in a superior release profile and patient compliance. Finally, prepared biloaded capsules were discovered to exhibit both an IR and an SR profile. 1. Introduction Atorvastatin (ATN) is a synthetic lipid-lowering agent present as a calcium salt. ATN calcium belongs to the second generation of statins. ATN lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and, subsequently, cholesterol biosynthesis in the liver, and it increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. Production of LDL and the number of LDL particles Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2022, Article ID 4995508, 11 pages https://doi.org/10.1155/2022/4995508